Ipsen markets more than twenty medicines in more than 115 countries and has a direct commercial presence in more than 30 states. Ipsen's research and development...
Gilead said that it expects the agreement with Tentarix to reduce its earnings per share (EPS) from 3 to 4 cents in 2023. In addition, the...
Currently, the British multinational does not have any project related to this type of therapy. AstraZeneca tried to reach this market through a negotiation with Moderna, but...
Neuralink, Elon Musk's brain-computer interface startup, has just raised $280 million for its brain implant technology. Initially, Neuralink aims to treat Alzheimer's and paralysis. It will...
Roche recently partnered with Alnylam for the development and commercialization of a treatment for hypertension in patients with high cardiovascular risk. The Swiss company makes an initial...
Doctomatic uses artificial intelligence capable of reading data from images to find out if a person may or may not have a disease. The company's clients...
In 2023, Bayer hoped to have a sales volume of between €51 billion and €52 billion, which is now reduced to between €48.5 billion and €49.5 billion,...
Novartis is aiming for its annual sales to grow in the high single digits this year when it previously estimated they would grow in the mid-single...
Dive Medical was incorporated as a company in 2020 and has raised €2.2 million between public and private investment. The company has developed its device with which...
Looking at application sectors, although the activity of biotech companies in Italy remains largely concentrated in human health (just under 50 percent), between 2014 and 2021...